Firms to co-develop heart-failure drug in potential $430M deal

05/10/2013 | American City Business Journals

Trevena and Forest Laboratories entered into a licensing-option deal involving TRV027, Trevena's drug candidate for acute heart failure. Forest agreed to make a $30 million equity stake in Trevena in exchange for an option to license TRV027. If Forest exercises its option, Trevena will be entitled to as much as $430 million in milestone fees plus sales royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI